Neurocrine Biosciences Unveils Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients at ENDO 2025
San Diego, CA – July 14, 2025 – Neurocrine Biosciences, a leading neuroscience-focused company, today announced the presentation of compelling one-year data demonstrating the sustained efficacy of CRENESSITY® (crinecerfont) in adult patients. These important findings were shared at ENDO 2025, the annual meeting of the Endocrine Society, a premier gathering for endocrinology professionals.
The presented data highlights the continued positive impact of CRENESSITY® on adult patients with certain conditions, underscoring its potential as a long-term therapeutic option. Neurocrine Biosciences has been dedicated to advancing treatments for neurological and endocrine disorders, and these latest results from the CRENESSITY® program are a testament to that commitment.
CRENESITY® (crinecerfont) is a first-in-class, oral selective corticotropin-releasing factor 1 (CRF1) receptor antagonist. Its mechanism of action targets the hypothalamic-pituitary-adrenal (HPA) axis, a key regulator of the body’s stress response. By blocking the CRF1 receptor, CRENESSITY® aims to modulate the downstream release of hormones involved in stress and adrenal function.
The one-year data presented at ENDO 2025 offers valuable insights into the durability of CRENESSITY®’s effects. For adult patients who have been receiving the treatment, the findings suggest that the benefits observed in earlier studies are maintained over an extended period. This sustained efficacy is crucial for managing chronic conditions where consistent therapeutic response is essential for improving patient quality of life.
Neurocrine Biosciences is committed to a rigorous scientific approach, and the presentation of these one-year data at a respected conference like ENDO 2025 reflects their dedication to transparently sharing advancements in their pipeline. The company continues to invest in research and development to better understand the full therapeutic potential of CRENESSITY® and its impact on patients’ lives.
Further details regarding the specific outcomes and methodologies of the one-year study are expected to be shared through scientific publications and future presentations. Neurocrine Biosciences remains focused on its mission to develop innovative treatments that address significant unmet medical needs in neuroscience and endocrinology.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025’ at 2025-07-14 12:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.